Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > ORGANIZATION
ORGANIZATION
- Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform
December 23, 2021
- INES Launches Cervical Cancer Awareness Project in Japan
December 10, 2021
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- JEMA Calls for Disclosure of Expected 3-Month Inventory Levels, Smaller Number of Companies per API
December 2, 2021
- Pharma, Wholesaler Leaders Hold 1st Meeting with PM Kishida
November 30, 2021
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
- JPMA Director Gets Sarcastic on MOF’s Data Presentation on Drug Costs
November 19, 2021
- Sales Reps in Japan Log Record Decline in FY2020, Down for 7 Consecutive Years
November 17, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- JPWA Vows to Boost Compliance after New Bid-Rigging Probe
November 12, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
- Japan No. 3 Originator Country in Global Top 100 Drug List in 2020: JPMA Think Tank
November 11, 2021
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
- Kazuhiko Ezawa to Become Chuikyo JMA Rep after Matsumoto
October 28, 2021
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…